EQT Life Sciences and Nextech Lead $183 Million Series C for Electra Therapeutics

Electra Therapeutics has raised USD 183 million in Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and existing investors, announced in a press release.

The funding will support a registrational Phase 2/3 clinical study of Electra’s lead program, ELA026, in secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no approved therapies. The study aims to confirm earlier Phase 1b results showing 100 percent survival at 8 weeks in frontline-treated patients.

Electra will also use the proceeds to expand ELA026 into hematologic cancers and to advance its second program, ELA822, which targets immune-mediated diseases. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.

EQT Life Sciences partner Christoph Broja will join Electra’s board as an observer, supporting the company’s ongoing clinical and development initiatives.